samedan logo
 
 
spacer
home > pmps > spring 2004 > building a healthier system: improving efficiency and safety in the pharmaceutical supply chain
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Building a Healthier System: Improving Efficiency and Safety in the Pharmaceutical Supply Chain

A question frequently asked of the industry reflects on how we can be sure that the pharmaceutical products sold by retailers have been sourced from a reputable and reliable company. Increasingly the answer to that question is: radio frequency identification (RFID), which offers a new technological solution for manufacturers and distributors. RFID tags are safe, secure, read only chips that can be used to improve the integrity and security of the pharmaceutical supply chain. The chips contain a unique electronic code for each individual item, which makes it far harder for counterfeiters to infiltrate legitimate distribution and the retail supply chain.

Pharmaceutical companies increasingly recognise the importance of traceability and due diligence within the pharmaceutical supply chain. There is a clear need for technological solutions that can prevent the misdirection of drugs and can stop counterfeit products from entering the legitimate pharmaceutical supply chain. RFID tags can help mitigate the risks associated with the production and distribution of pharmaceuticals goods.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Peter Jones, Head of Mu Solutions at Hitachi

Peter Jones has worked for Hitachi Europe for three years and was involved in establishing the Mu Solutions business. Peter is responsible for sales and marketing as well as technology development for system's solutions and related software packages. Previously, Peter worked for 15 years in the financial sector for a number of blue chip companies including Citibank and Logica. These roles have covered the complete system's development life cycle through to the creation of new business models and service propositions. Peter's experience spans technical and project management roles, through to business development of new and emerging technologies.

spacer
Peter Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen).
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement